Last updated on April 2019

A Study of Intermittent Oral Dosing of ASP1517 in Non-Dialysis Chronic Kidney Disease Patients With Anemia


Brief description of study

The objective of this study is to evaluate the efficacy and safety of ASP1517 when converted from recombinant human erythropoietin (rHuEPO) or darbepoetin alfa (DA), compared to DA in the treatment of anemia in non-dialysis chronic kidney disease patients. Another uncontrolled cohort will be included to evaluate the efficacy and safety of ASP1517 in patients converted from epoetin beta pegol (CERA). This study will also assess the safety/efficacy of long term treatment of ASP1517 (52 weeks).

Detailed Study Description

This study consists of the following three cohorts. Cohort 1; subjects converted from rHuEPO or DA to ASP1517, Cohort 2; subjects converted from rHuEPO or DA to DA, Cohort 3; subjects converted from epoetin beta pegol (CERA) to ASP1517. In Cohort 1 and 3, ASP1517 will be administered orally for 52 weeks. In Cohort 2, DA will be administered subcutaneously for 24 weeks.

Clinical Study Identifier: NCT02988973

Contact Investigators or Research Sites near you

Start Over

Site JP00009

Aichi, Japan

Site JP00021

Aichi, Japan

Site JP00030

Aichi, Japan

Site JP00051

Aichi, Japan

Site JP00003

Chiba, Japan

Site JP00038

Ehime, Japan

Site JP00044

Ehime, Japan

Site JP00014

Fukui, Japan

Site JP00008

Fukuoka, Japan

Site JP00013

Fukuoka, Japan

Site JP00033

Fukuoka, Japan

Site JP00040

Fukuoka, Japan

Site JP00042

Fukuoka, Japan

Site JP00054

Fukuoka, Japan

Site JP00057

Fukuoka, Japan

Site JP00058

Fukuoka, Japan

Site JP00041

Gifu, Japan

Site JP00002

Gunma, Japan

Site JP00032

Hiroshima, Japan

Site JP00037

Hiroshima, Japan

Site JP00039

Hiroshima, Japan

Site JP00050

Hiroshima, Japan

Site JP00007

Hokkaido, Japan

Site JP00049

Hokkaido, Japan

Site JP00022

Hyogo, Japan

Site JP00017

Ibaraki, Japan

Site JP00019

Ibaraki, Japan

Site JP00023

Ibaraki, Japan

Site JP00028

Ibaraki, Japan

Site JP00046

Ibaraki, Japan

Site JP00052

Ibaraki, Japan

Site JP00053

Ibaraki, Japan

Site JP00035

Ishikawa, Japan

Site JP00031

Iwate, Japan

Site JP00001

Kanagawa, Japan

Site JP00016

Kanagawa, Japan

Site JP00047

Kanagawa, Japan

Site JP00048

Kanagawa, Japan

Site JP00045

Kyoto, Japan

Site JP00012

Miyagi, Japan

Site JP00018

Nagano, Japan

Site JP00036

Nagano, Japan

Site JP00026

Niigata, Japan

Site JP00034

Oita, Japan

Site JP00055

Okayama, Japan

Site JP00005

Osaka, Japan

Site JP00011

Osaka, Japan

Site JP00027

Osaka, Japan

Site JP00056

Osaka, Japan

Site JP00004

Saitama, Japan

Site JP00020

Saitama, Japan

Site JP00029

Saitama, Japan

Site JP00006

Tokyo, Japan

Site JP00015

Tokyo, Japan

Site JP00024

Tokyo, Japan

Site JP00025

Tokyo, Japan

Site JP00043

Tokyo, Japan

Site JP00010

Toyama, Japan

Site JP00059

Tokyo, Japan

Site JP00060

Tokyo, Japan

Site JP00064

Hokkaido, Japan

Site JP00061

Osaka, Japan

Site JP00062

Tokyo, Japan

Site JP00065

Fukuoka, Japan

Site JP00067

Tokyo, Japan

Site JP00066

Hyogo, Japan

Site JP00068

Hyogo, Japan

Site JP00063

Tokyo, Japan

Site JP00069

Osaka, Japan

Site JP00071

Kagoshima, Japan

Site JP00070

Tokyo, Japan

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.